Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: Findings from the phase 3 establish clinical trials

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7198-7204

  Lodise, Thomas P ^a   Fang, Edward ^b   Minassian, Sonia L ^c   Prokocimer, Philippe G ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Cubist Pharmaceuticals   (United States)

^c Minassian Biostatistics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; TEDIZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; BACTERIAL SKIN DISEASE; BLEEDING; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL SKIN INFECTIONS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BLOOD PLATELETS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PLATELET COUNT; STAPHYLOCOCCAL SKIN INFECTIONS; TETRAZOLES;

EID: 84912083877     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03509-14     Document Type: Article

References (34)

1. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52: 4442-4447. http://dx.doi .org/10.1128/AAC.00859-08.
2. Louie A, Liu W, Kulawy R, Drusano GL. 2011. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against me-thicillin- susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob. Agents Chemother. 55: 3453-3460. http://dx.doi.org/10.1128/AAC.01565-10.
3. Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. 2012. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Grampositive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 56:4608-4613. http://dx.doi.org/10 .1128/AAC.00458-12.
4. Locke JB, Finn J, Hilgers M, Morales G, Rahawi S, G CK, Picazo JJ, Im W, Shaw KJ, Stein JL. 2010. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob. Agents Chemother. 54:5337-5343. http://dx.doi.org/10.1128/AAC .00663-10.
5. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. 2013. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309:559-569. http://dx.doi.org/10.1001/jama.2013.241.
6. Moran GJ, Fang E, Corey RG, Das AF, De Anda C, Prokocimer P. 2014. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect. Dis. 14:696-705. http://dx.doi .org/10.1016/S1473-3099(14)70737-6.
7. Food and Drug Administration. 2010. Draft guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Food and Drug Administration, Silver Spring, MD. http://www.regulations .gov/#!documentDetail;D=FDA-2010-D-0433-0002.
8. US Food and Drug Administration. 2013. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Food and Drug Administration, Silver Spring, MD. http://www.fda .gov/downloads/Drugs/./Guidances/ucm071185.pdf.
9. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann. N. Y. Acad. Sci. 1241:48-70. http://dx.doi.org/10.1111/j.1749 -6632.2011.06330.x.
10. Attassi K, Hershberger E, Alam R, Zervos MJ. 2002. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34:695-698. http://dx .doi.org/10.1086/338403.
11. Orrick JJ, Johns T, Janelle J, Ramphal R. 2002. Thrombocytopenia secondary to linezolid administration: what is the risk? Clin. Infect. Dis. 35:348-349. http://dx.doi.org/10.1086/341310.
12. Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Ishihara M, Wada Y, Tsuchida T, Uchino M, Ikeuchi H. 2011. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J. Infect. Chemother. 17:382-387. http://dx.doi.org/10.1007 /s10156-010-0182-1.
13. Pfizer, Inc. 2013. Zyvox package insert. Pfizer Inc., New York, NY.
14. Wazny LD, Ariano RE. 2000. Evaluation and management of druginduced thrombocytopenia in the acutely ill patient. Pharmacotherapy 20:292-307. http://dx.doi.org/10.1592/phco.20.4.292.34883.
15. Newland AC. 1995. The problem of thrombocytopenia and its management. Anticancer Drugs 6(Suppl 5):S65-S73.
16. Visentin GP, Liu CY. 2007. Drug-induced thrombocytopenia. Hematol. Oncol. Clin. North Am. 21:685-696, vi. http://dx.doi.org/10.1016/j.hoc .2007.06.005.
17. Reddy JC, Shuman MA, Aster RH. 2004. Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch. Intern. Med. 164:218-220. http://dx.doi.org/10.1001/archinte.164.2.218.
18. Aster RH, Bougie DW. 2007. Drug-induced immune thrombocytopenia. N. Engl. J. Med. 357: 580-587. http://dx.doi.org/10.1056 /NEJMra066469.
19. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. 2003. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch. Intern. Med. 163:2518-2524. http://dx.doi .org/10.1001/archinte.163.20.2518.
20. th edition). Chest 133(Suppl):340S-380S. http://dx.doi.org/10.1378/chest.08-0677.
21. Patel N, VanDeWall H, Tristani L, Rivera A, Woo B, Dihmess A, Li HK, Smith R, Lodise TP. 2012. A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. J. Antimicrob. Chemother. 67:727-735. http://dx.doi.org/10.1093 /jac/dkr522.
22. National Institutes of Health. 2007. Adult toxicity table. National Institutes of Health, Division of Microbiology and Infectious Diseases, Bethesda, MD. http://www.niaid.nih.gov/LabsAndResources/resources /DMIDClinRsrch/Documents/dmidadulttox.pdf.
23. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, Corey GR. 2011. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592. http://dx .doi.org/10.1128/AAC.00076-10.
24. th Annu. Meet., Washington, DC.
25. nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
26. Food and Drug Administration. 2014. Briefing document: tedizolid phosphate tablets and injection, p 11. Anti-Infect. Drug Advisory Comm. Meet., 31 March 2014. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeti ngMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390789.pdf.
27. Lin Y-H, Wu V-C, Tsai I-J, Ho Y-L, Hwang J-J, Tsau Y-K, Wu C-Y, Wu K-D, Hsueh P-R. 2006. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int. J. Antimicrob. Agents 28:345-351. http://dx.doi.org/10.1016/j.ijantimicag.2006.04.017.
28. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. 2010. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int. J. Antimicrob. Agents 36:179-181. http://dx.doi.org/10.1016/j .ijantimicag.2010.02.019.
29. Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K. 2013. High plasma linezolid concentration and impaired renal function affect development of lin-ezolid- induced thrombocytopenia. J. Antimicrob. Chemother. 68:2128-2133. http://dx.doi.org/10.1093/jac/dkt133.
30. Cossu AP, Musu M, Mura P, De Giudici LM, Finco G. 2014. Linezolidinduced thrombocytopenia in impaired renal function: is it time for a dose adjustment?Acase report and review of literature. Eur. J. Clin. Pharmacol. 70:23-28. http://dx.doi.org/10.1007/s00228-013-1585-6.
31. Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M, Hopkins NK, Jungbluth GL. 2003. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob. Agents Chemother. 47:2775-2780. http://dx.doi.org/10.1128/AAC.47.9.2775-2780.2003.
32. Dryden MS. 2011. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother. 66(Suppl 4):S7-S15.
33. Cubist Pharmaceuticals. 2014. Sivextro (tedizolid phosphate) package insert. Cubist Pharmaceuticals US, Lexington, MA.
34. th Eur. Congr. Clin. Microbiol. Infect. Dis., Helsinki, Finland.